Ask AI
ProCE Banner Activity

Conference to Clinic—Advancing Integration of BTK Inhibitors in CLL/SLL Treatment: Expert Insights on Evolving Approaches to Optimize Care

Slideset

These downloadable slides highlight expert perspectives on optimizing the use of BTK inhibitors in the treatment of CLL/SLL. Here, experts review key clinical data, evolving treatment strategies, and evidence-based recommendations for therapy selection, sequencing, and management of adverse events to improve patient outcomes.

Released: October 22, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Faculty Disclosure

Primary Author

Sameh Gaballa, MD: consultant/advisor/speaker: AbbVie, Adaptive Biotechnologies, ADC Therapeutics, AstraZeneca, BeOne, Incyte, Ipsen, Lilly, Regeneron.

Nitin Jain, MD: advisor/honoraria: AbbVie, Adaptive, AstraZeneca, Autolus, BeOne, Bristol Myers Squibb, Cellectis, Genentech, Janssen, Kite/Gilead, Lilly, Novalgen, Nurix, Pharmacyclics, SERB Pharma; research: AbbVie, Adaptive, ADC Therapeutics, Ascentage, AstraZeneca, BeOne, Bioheng, Bristol Myers Squibb, Carna, Cellectis, Fate, Genentech, Kisoji, Kite/Gilead, Lilly, Mingsight, Newave, Novartis, Precision Biosciences, Pharmacyclics, Sana, Takeda, Triarm, Ubix.